Imaging has a central role in the context of focal therapy (FT) for prostate cancer (PCa). Prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) is a novel imaging modality that combines the morpho-functional information of MRI with the molecular characterization of PET Some papers reported the potential advantages of PSMA PET/MRI in different clinical scenarios. Limited evidence on PSMA PET/MRI is available in the setting of FT. PSMA PET/MRI can be an effective imaging modality for detecting primary PCa and seems to provide accurate local staging of primary PCa. PSMA PET/MRI also shows high performance for restaging and detecting tumor recurrence. The higher soft-tissue contrast and the reduction of ionizing radiation are the main advantages reported in the literature compared to PET/computed tomography. PSMA PET/MRI could represent a turning point in the management of patients with PCa in the context of FT. Further studies are needed to confirm its applications in this specific clinical setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918526 | PMC |
| http://dx.doi.org/10.5306/wjco.v12.i2.61 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Pilot Study of PSMA PET/CT and MRI Fusion for Prostate Cancer: Software to Replace PET/MRI Hardware.
J Clin Med
December 2024
Herston Biofabrication Institute, Metro North Health, Herston, QLD 4029, Australia.
: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT), in combination with magnetic resonance imaging (MRI), may enhance the diagnosis and staging of prostate cancer. Image fusion of separately acquired PET/CT and MRI images serve to facilitate clinical integration and treatment planning. This study aimed to investigate different PSMA PET/CT and MRI image fusion workflows for prostate cancer visualisation.
View Article and Find Full Text PDFPreoperative detection of extraprostatic tumor extension in patients with primary prostate cancer utilizing [Ga]Ga-PSMA-11 PET/MRI.
Insights Imaging
December 2024
Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Objectives: Radical prostatectomy (RP) is a common intervention in patients with localized prostate cancer (PCa), with nerve-sparing RP recommended to reduce adverse effects on patient quality of life. Accurate pre-operative detection of extraprostatic extension (EPE) remains challenging, often leading to the application of suboptimal treatment. The aim of this study was to enhance pre-operative EPE detection through multimodal data integration using explainable machine learning (ML).
View Article and Find Full Text PDFProspects of nano-theranostic approaches against breast and cervical cancer.
Biochim Biophys Acta Rev Cancer
November 2024
Department of Clinical and Translational Research, Chittaranjan National Cancer Institute, 37 S.P. Mukherjee Road, Kolkata 700 026, India. Electronic address:
The bottleneck on therapeutics and diagnostics is removed by an alternate approach known as theranostics which combines both therapeutics and diagnostics within a single platform. Due to this "all in one" nature of theranostics, it is now extensively applied in the medicinal field mainly in cancer treatment over the conventional therapy. Recently, FDA approval of lutetium 177 (177Lu) DOTATATE and 177Lu-PSMA-based radionuclide theranostics are clinically used and very few theranostics specific to breast cancer are in clinical trials.
View Article and Find Full Text PDF[Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma.
Eur J Nucl Med Mol Imaging
November 2024
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei Province, China.
Purpose: Radiolabeled probes targeting prostate-specific membrane antigen (PSMA) have been used in prostate cancer. Moreover, PSMA is also overexpressed on neovessels in hepatocellular carcinoma (HCC). This study aimed to preliminarily evaluate the diagnostic effectiveness of [Ga]Ga-PSMA-617 PET/MRI for HCC.
View Article and Find Full Text PDFEnhancing the diagnostic capacity of [F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study.
EJNMMI Rep
November 2024
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany.
Background: To investigate the ability of artificial intelligence (AI)-based and semi-quantitative dynamic contrast enhanced (DCE) multiparametric MRI (mpMRI), performed within [F]-PSMA-1007 PET/MRI, in differentiating benign from malignant prostate tissues in patients with primary prostate cancer (PC).
Results: A total of seven patients underwent whole-body [F]-PSMA-1007 PET/MRI examinations including a pelvic mpMRI protocol with T2w, diffusion weighted imaging (DWI) and DCE image series. Conventional analysis included visual reading of PET/MRI images and Prostate Imaging Reporting & Data System (PI-RADS) scoring of the prostate.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!